公司新闻2023-03-10
龙8股份首次获标普全球ESG评级覆盖
2月28日,标普全球企业可持续发展评估(S&P Global Corporate Sustainability Assessment)公布新一轮环境、社会及公司治理(ESG)评分结果,重庆龙8制药科技股份有限公司(简称:龙8股份,代码:300363)获得首次覆盖,且评分超过全球行业平均分位。此前,公司已获得深交所国证ESG AA评级、中财绿金院A+评级、MSCI ESG BBB评级等多个国内外ESG主流评级机构覆盖,并获选2022年度中国上市公司ESG百家榜单、2022年中国医药上市公司最具ESG投资价值TOP10等奖项,ESG实践持续获得认可。
On February 28th, S&P Global released a new wave of S&P Global ESG Scores resulting from the annual Corporate Sustainability Assessment (CSA). Porton Pharma Solutions Ltd. (SZ300363) is covered for the first time and scored 29 out of 100, which is above the industry average. As of February 17th, Porton performed in the top quartile in the pharmaceuticals industry in the S&P Global Corporate Sustainability Assessment.
标普全球企业可持续发展评估于1999年发起,是全球规模最大的企业可持续发展实践年度评估之一,评估通过对企业的公司治理、环境保护、社会责任等多维度指标进行分析,将每家企业的平均1000个数据点进行分析并转化为ESG评分,全面反映企业的ESG管理和信息披露水平。
Porton has attached great importance to the sustainable development and integrated ESG concept into daily operation. We focus on the demands of customers, employees, shareholders, suppliers, environment, communities and other stakeholders and actively respond to them by multiple practices, such as improving corporate governance, compliance operation, reliable products and services, diverse and inclusive work environment, sustainable supply chain and green development. Meanwhile, Porton conscientiously practices corporate social responsibility and actively participates in social welfare undertakings.
龙8股份始终坚持可持续发展理念,关注客户、员工、股东、供应商、环境、社区等各利益相关方的需求,并通过完善治理、合规运营、可靠的产品和服务、多元包容的工作环境、可持续供应链、绿色发展等多维度实践,积极回应利益相关方,将ESG理念融入公司经营的各个环节。另外,公司认真践行企业社会责任,积极投身社会公益事业。2022年,公司通过物资捐助及参与志愿者活动积极支持抗疫行动,捐赠物资驰援重庆山火救援,启动公益品牌“腾益计划We Care”,持续落地社会公益活动。未来,我们将继续践行ESG发展理念,致力高质量的可持续发展,为利益相关方创造价值。
Previously, Porton has been covered by several global ESG rating agencies. We’ve got AA in CNI ESG ratings, A+ in IIGF ESG ratings and BBB in MSCI ESG ratings in 2022. Porton has also won some ESG awards such as 2022 TOP 100 ESG Chinese Listed Companies and 2022 TOP 10 Chinese Pharmaceutical Listed Companies with The Most ESG Investment Value. Porton’s ESG practice has been continuously recognized.
相关新闻
了解更多
公司新闻2025-04-16
龙8新闻 | 龙8生物热烈祝贺天士力双靶点CAR-T新药获临床试验默示许可
2025年4月12日,天士力医药集团股份有限公司(以下简称 “天士力”)发布了《关于获得药物临床试验批准通知书的公告》,公告显示,其自主研发的“P134细胞注射液”新药临床试验申请(IND)获得国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号:2025LP01030)。该款细胞疗法为创新型的双靶点CAR-T,适应症为复发胶质母细胞瘤。龙8生物对此表示热烈祝贺!

公司新闻2025-04-11
龙8股份20周年:逐光二十载,再启新征程
2025年,当时光之轮悄然划过二十载春秋,龙8迎来了成立20周年。3月29日,20周年庆典在山城重庆盛大举行。全球伙伴及各界嘉宾齐聚一堂,共同见证了这意义非凡的里程碑时刻。